CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of its Spikevax 2025-2026 formula, targeting the SARS-CoV-2 variant LP.8.1. The submission is based on guidance from the U.S. FDA, which advised that COVID-19 vaccines should be updated to a monovalent JN.1 lineage, with a preference for the LP.8.1 variant. About Moderna Moderna is a leader in the creation of t

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA. Results from the SACHI China Phase III study of savolit

SHANGHAI, May 22, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced gastric/gastroesophageal junction cancer (G/GEJC) in China (CT041-ST-01, NCT04581473) is available on th

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the US Food & Drug Administration (FDA) provided endorsement of the plans for the Phase IIb trial of CS1 as noted by the official meeting minutes from the Type C-meeting held on April 21. The next clinical development step of CS1 is a larger, placebo-controlled Phase IIb trial aiming to further eval

Fresenius Management Board with Wolfgang Kirsch, Chairman of the Supervisory Board (third from left) Download Image (JPG 2.76 MB) Michael Sen, Fresenius CEO Michael Sen, Fresenius CEO Michael Sen, Fresenius CEO Michael Sen, Fresenius CEO Annual General Meeting 2025 Contact Timo Lindemann T +49 (0) 6172 608-7939 timo.lindemann@fresenius.com Documents Text as PDF document (PDF, 79 KB) The disciplined implementation of #FutureFresenius has made Fresenius a simpler, more focused, and stronger compan

Pictured: GSK’s headquarters in West London/iStock iStock, Magdalena Wygralak The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD for their blockbuster antibody Dupixent. After failing to meet its target decision date earlier this month, the FDA on Thursday approved the expansion of GSK ’s anti-IL-5 antibody Nucala to cover chronic obstructive pulmonary disease. The approval opens up the use of Nucala to patients with

iStock, May Lim The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines. The FDA’s Vaccines and Related Biological Products Advisory Committee voted unanimously on Thursday for a monovalent COVID-19 shot that includes coverage of the virus’ JN.1 lineage, the same recommendation it made last year. But looming over Thursday’s discussions—Leerink analysts in a note called it “the elephant in the room—was the FDA’s recently announ

iStock, beast01 Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the first-line setting for this indication. Merus’ investigational bispecific antibody petosemtamab, when combined with Merck’s mega-blockbuster Keytruda, led to a nearly 80% overall survival rate when used as a frontline treatment option for certain patients with head and neck cancer, according to a Phase II readout posted Thursday. Writing to investors early o

VANCOUVER, May 23rd, 2025 – TheNewswire - Aequus Pharmaceuticals Inc. (TSX-V: AQS) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, and Luvo Medical Technologies Inc. (“Luvo”), today announce the signing of an Asset Purchase Agreement for the sale of Zimed® PF (the “Transaction”). Unless otherwise noted, all figures are in Canadian currency. “Since Zimed® PF was launched in 2023 in collaborat

BioNTech has announced that it will be investing up to £1bn into the UK over the next ten years in an effort to widen its regional research and development (R&D) activities. The UK government has also agreed to award the company up to £129m, representing one of the largest grants of its kind in UK history for a pharmaceutical company. The agreement between BioNTech’s subsidiary BioNTech UK and the UK government is focused on accelerating clinical trials for the company’s oncology drug candidates